Upgrade to SI Premium - Free Trial

COMPASS Pathways plc (CMPS)

11.93 -0.25 (2.05%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/30/26)

Latest Headlines

B.Riley Reiterates Buy Rating on Compass Pathways (CMPS) July 20, 2026 7:10 AM - StreetInsider Compass Pathways study finds COMP360 support differs from psychotherapy July 16, 2026 6:35 AM - StreetInsider Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy July 16, 2026 6:35 AM - BizWire FDA sets public hearing on psychedelics for September 14, Jefferies sees FDA willing to move on COMP360 July 13, 2026 1:04 PM - StreetInsider TD Cowen Reiterates Buy Rating on Compass Pathways (CMPS) July 13, 2026 6:26 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Compass Pathways (CMPS) July 9, 2026 6:49 AM - StreetInsider Evercore ISI Upgrades Compass Pathways (CMPS) to Outperform July 8, 2026 9:42 AM - StreetInsider Canaccord Reiterates Buy Rating on Compass Pathways (CMPS) July 8, 2026 6:49 AM - StreetInsider Compass Pathways (CMPS) PT Raised to $21 at Stifel July 7, 2026 4:33 PM - StreetInsider TD Cowen on Compass Pathways (CMPS): 'We think DEA reclassification to schedule 3 after approval is likely' July 7, 2026 3:53 PM - StreetInsider Wolfe Research on Compass Pathways (CMPS): 'we expect the stock to regain strong momentum after this pullback' July 7, 2026 3:52 PM - StreetInsider Oppenheimer on Compass Pathways (CMPS): 'Reinforced Durability Strengthens Launch Prospects' July 7, 2026 12:11 PM - StreetInsider Compass Pathways (CMPS) PT Raised to $25 at BTIG, 'executed nearly flawlessly on everything within its control' July 7, 2026 12:10 PM - StreetInsider Jefferies on Compass Pathways (CMPS): 'We remain 75-85%+ confident the FDA approves COMP360 (oral psilocybin) around YE:26/early 2027' July 7, 2026 10:26 AM - StreetInsider Form 8-K COMPASS Pathways plc For: Jul 07 July 7, 2026 6:33 AM - SEC Filing Compass Pathways reports 6-month data from second psilocybin Phase 3 trial July 7, 2026 6:30 AM - StreetInsider Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile July 7, 2026 6:30 AM - BizWire Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026 July 6, 2026 8:30 AM - Globe NewsWire Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 2, 2026 6:30 AM - BizWire Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity June 30, 2026 9:00 AM - StreetInsider Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer June 29, 2026 7:30 AM - Globe NewsWire Compass Pathways (CMPS) PT Raised to $20 at Canaccord June 26, 2026 7:37 AM - StreetInsider Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 5, 2026 6:30 AM - BizWire DATAcc by DiMe releases first set of digital measures built specifically for common mental health disorders June 4, 2026 10:45 AM - PR NewsWire FundaMental Pharma names Dr. Hans Eriksson as chief medical officer June 2, 2026 3:30 AM - StreetInsider FundaMental Pharma appoints depression drug developer Dr. Hans Eriksson as Chief Medical Officer to advance its lead treatment-resistant depression candidate June 2, 2026 3:30 AM - Globe NewsWire TD Cowen on Compass Pathways (CMPS) Amid +10% Gain Today: 'e continue to model '360 approval in 1H27' June 1, 2026 1:43 PM - StreetInsider Form 4 COMPASS Pathways plc For: May 27 Filed by: Karydas Daphne May 29, 2026 5:32 PM - SEC Filing Form 4 COMPASS Pathways plc For: May 27 Filed by: SANTINI GINO May 29, 2026 5:27 PM - SEC Filing Form 4 COMPASS Pathways plc For: May 27 Filed by: Gover Justin D. May 29, 2026 5:18 PM - SEC Filing Form 4 COMPASS Pathways plc For: May 27 Filed by: JONAS JEFFREY M May 29, 2026 5:16 PM - SEC Filing Form 4 COMPASS Pathways plc For: May 27 Filed by: Riley Wayne Joseph May 29, 2026 5:14 PM - SEC Filing Form 4 COMPASS Pathways plc For: May 27 Filed by: McQuade Robert May 29, 2026 5:12 PM - SEC Filing Form 4 COMPASS Pathways plc For: May 27 Filed by: Norton David Y May 29, 2026 5:12 PM - SEC Filing Form 4 COMPASS Pathways plc For: May 27 Filed by: Tregoning Kathleen May 29, 2026 5:11 PM - SEC Filing Form 3 COMPASS Pathways plc For: May 27 Filed by: Tregoning Kathleen May 29, 2026 5:09 PM - SEC Filing Form 8-K COMPASS Pathways plc For: May 27 May 28, 2026 6:43 AM - SEC Filing Compass Pathways elects Kathleen Tregoning to board of directors May 28, 2026 6:30 AM - StreetInsider Compass Pathways Elects Kathleen Tregoning to Board of Directors May 28, 2026 6:30 AM - BizWire Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026 May 26, 2026 6:30 AM - BizWire H.C. Wainwright Reiterates Buy Rating on Compass Pathways (CMPS) May 22, 2026 6:52 AM - StreetInsider Wolfe Research Starts Compass Pathways (CMPS) at Outperform May 22, 2026 5:53 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Compass Pathways (CMPS) May 18, 2026 7:03 AM - StreetInsider Compass Pathways (CMPS) PT Raised to $20 at Maxim Group May 15, 2026 8:44 AM - StreetInsider Form SCHEDULE 13G/A COMPASS Pathways plc Filed by: RTW INVESTMENTS, LP May 15, 2026 8:19 AM - SEC Filing Compass Pathways (CMPS) PT Raised to $17 at Morgan Stanley May 14, 2026 8:52 AM - StreetInsider Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026 May 14, 2026 6:30 AM - BizWire TD Cowen Reiterates Buy Rating on Compass Pathways (CMPS) May 13, 2026 3:34 PM - StreetInsider BTIG Reiterates Buy Rating on Compass Pathways (CMPS) May 13, 2026 2:33 PM - StreetInsider Compass Pathways (CMPS) PT Raised to $22 at RBC Capital May 13, 2026 1:16 PM - StreetInsider Form F-6EF COMPASS Pathways plc/ADR Filed by: Citibank,N.A./ADR May 13, 2026 6:46 AM - SEC Filing COMPASS Pathways plc (CMPS) Tops Q1 EPS by 13c May 13, 2026 6:34 AM - StreetInsider Form 8-K COMPASS Pathways plc For: May 13 May 13, 2026 6:31 AM - SEC Filing Form 10-Q COMPASS Pathways plc For: Mar 31 May 13, 2026 6:31 AM - SEC Filing Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights May 13, 2026 6:30 AM - BizWire Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026 May 6, 2026 6:30 AM - BizWire Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 6, 2026 6:25 AM - BizWire Jefferies Starts Compass Pathways (CMPS) at Buy May 4, 2026 2:12 AM - StreetInsider Silo Pharma’s PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD April 29, 2026 9:08 AM - Globe NewsWire H.C. Wainwright Reiterates Buy Rating on Compass Pathways (CMPS) April 28, 2026 6:44 AM - StreetInsider TD Cowen on Compass Pathways (CMPS) FDA Grant: 'meaningful positive and expected in light of last Saturday’s Executive Order' April 24, 2026 3:41 PM - StreetInsider Oppenheimer on Compass Pathways (CMPS) FDA Grant: 'reinforcing our conviction considering the earlier launch timeline for COMP360 in TRD' April 24, 2026 1:24 PM - StreetInsider Morgan Stanley on Compass Pathways (CMPS): 'we view today’s update as incrementally encouraging' April 24, 2026 1:06 PM - StreetInsider Compass Pathways receives FDA rolling review for psychedelic depression drug April 24, 2026 10:37 AM - StreetInsider Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher April 24, 2026 10:37 AM - BizWire FDA advances psychedelic drug studies for mental health treatment April 24, 2026 9:10 AM - StreetInsider B.Riley Starts Compass Pathways (CMPS) at Buy April 24, 2026 3:49 AM - StreetInsider Full Article List